Mohammad Vaziri Shares Breakthrough Insights on Factor XI Inhibitors for Thrombosis Prevention and Safer Anticoagulation
Mohammad Vaziri, Thoracic Surgery Professional at IRAN University of Medical Sciences (IUMS), posted on LinkedIn:
”Key points
Factor XI (FXI) inhibitors aim to uncouple hemostasis from thrombosis, presenting a novel approach to anticoagulation, with a reduced risk of bleeding compared with that associated with traditional anticoagulant agents.
Several phase II studies indicate that FXI inhibitors decrease thrombotic complications dose-dependently, without corresponding increases in bleeding, suggesting a favourable safety profile.
FXI inhibitors showed non-inferiority and potential superiority to low-molecular-weight heparin for the prevention of venous thromboembolism in patients undergoing orthopaedic surgery, with minimal bleeding risks observed at therapeutic doses.
Milvexian and abelacimab are theoretically promising for reducing the risk of bleeding associated with thromboprophylaxis in patients with atrial fibrillation; phase III clinical trials of safety and efficacy are ongoing.
In phase II trials involving patients with non-cardioembolic ischaemic stroke, no significant benefit of FXI inhibitors was found in terms of the primary ischaemic end points, but future phase III trials might find benefits in selected patients with large-vessel atherosclerosis.
The ongoing LIBREXIA-ACS trial will assess the use of milvexian in 16,000 patients with recent acute coronary syndrome.”
Reaf the full article here.
Title: Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism
Authors: Davide Capodanno, John H. Alexander, M. Cecilia Bahit, John W. Eikelboom, C. Michael Gibson, Shaun G. Goodman, Vijay Kunadian, Gregory Y. H. Lip, Renato D. Lopes, Roxana Mehran, Shamir R. Mehta, Manesh R. Patel, Jonathan P. Piccini, Sunil V. Rao, Christian T. Ruff, P. Gabriel Steg, Jeffrey I. Weitz, Dominick J. Angiolillo
Stay updated with Hemostasis Today.
-
Nov 3, 2025, 08:23The 1st Participant in A New CHECK-NIRS Clinical Study is Enrolled!
-
Nov 3, 2025, 08:15Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
-
Nov 3, 2025, 07:10Lisa Shea Shares Key Takeaways from NORD Summit 2025
-
Nov 3, 2025, 06:49Darshan Doshi on Results of iMODERN and ILIAS ANOCA Studies Presented at TCT 2025
-
Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 3, 2025, 04:56Nirupama Ramadas and Erica Sparkenbaugh on Thromboinflammation in SCD
-
Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
-
Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 3, 2025, 09:24Stephen Cornelissen: It’s Not Just About Emergencies — It’s About Everyday Care, Chronic Conditions and Hope
-
Nov 3, 2025, 06:57Maria Elisa Mancuso Reflects on 2025 Annual Congress of the Italian Association of Hemophilia Centres
-
Nov 3, 2025, 05:46Chandra Viswanathan: When Blood Safety Fails, We All Bleed - A Call for Reform and Responsibility
-
Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
-
Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry